| __timestamp | Amicus Therapeutics, Inc. | Bausch Health Companies Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 20717000 | 2026300000 |
| Thursday, January 1, 2015 | 47269000 | 2682700000 |
| Friday, January 1, 2016 | 71151000 | 2810000000 |
| Sunday, January 1, 2017 | 88671000 | 2582000000 |
| Monday, January 1, 2018 | 127200000 | 2473000000 |
| Tuesday, January 1, 2019 | 169861000 | 2554000000 |
| Wednesday, January 1, 2020 | 156407000 | 2367000000 |
| Friday, January 1, 2021 | 192710000 | 2624000000 |
| Saturday, January 1, 2022 | 213041000 | 2625000000 |
| Sunday, January 1, 2023 | 275270000 | 2917000000 |
Unlocking the unknown
In the competitive landscape of the pharmaceutical industry, understanding the financial strategies of key players is crucial. Bausch Health Companies Inc. and Amicus Therapeutics, Inc. have shown distinct trends in their Selling, General, and Administrative (SG&A) expenses over the past decade.
From 2014 to 2023, Bausch Health consistently maintained higher SG&A expenses, peaking at nearly $2.9 billion in 2023, reflecting a strategic focus on expansive marketing and administrative operations. In contrast, Amicus Therapeutics, while starting with a modest $20 million in 2014, saw a dramatic increase of over 1,200% by 2023, reaching approximately $275 million. This surge indicates a significant scaling of operations and market presence.
These trends highlight the differing growth strategies: Bausch Health's steady investment in established markets versus Amicus Therapeutics' aggressive expansion. As the industry evolves, these financial strategies will play a pivotal role in shaping their future trajectories.
Cost Management Insights: SG&A Expenses for Takeda Pharmaceutical Company Limited and Bausch Health Companies Inc.
Operational Costs Compared: SG&A Analysis of Viatris Inc. and Bausch Health Companies Inc.
Intra-Cellular Therapies, Inc. and Amicus Therapeutics, Inc.: SG&A Spending Patterns Compared
Bio-Techne Corporation or Amicus Therapeutics, Inc.: Who Manages SG&A Costs Better?
Cytokinetics, Incorporated vs Bausch Health Companies Inc.: SG&A Expense Trends
SG&A Efficiency Analysis: Comparing PTC Therapeutics, Inc. and Amicus Therapeutics, Inc.
Bausch Health Companies Inc. or Soleno Therapeutics, Inc.: Who Manages SG&A Costs Better?
Bausch Health Companies Inc. vs Iovance Biotherapeutics, Inc.: SG&A Expense Trends
SG&A Efficiency Analysis: Comparing Bausch Health Companies Inc. and Amphastar Pharmaceuticals, Inc.
Cost Management Insights: SG&A Expenses for Bausch Health Companies Inc. and BioCryst Pharmaceuticals, Inc.
Amicus Therapeutics, Inc. and Soleno Therapeutics, Inc.: SG&A Spending Patterns Compared
SG&A Efficiency Analysis: Comparing Amicus Therapeutics, Inc. and Iovance Biotherapeutics, Inc.